/ /

Colleen E. McCarthy
Colleen McCarthy is a freelance writer based in the Cleveland area and a former editor of Optometry Times. She is a 2010 graduate of the University of Dayton with a degree in journalism.
Konan Medical launches EvokeDx
Konan Medical recently launched EvokeDx, the next-generation visual pathway diagnostics platform to assess visual evoked potentials (VEP) and electroretinograms (ERG).
B+L offers Ultra and BioTrue convenience pack
Bausch + Lomb recently launched a new convenience pack for eyecare practitioners and their patients that combines Bausch + Lomb Ultra contact lenses and Biotrue multi-purpose solution.
Gulden offers premium IOL lens inserts to help educate patients
Gulden Ophthalmics recently introduced its new Premium IOL lens inserts to use in conjunction with its Cataract Eye model to educate patients on their premium intraocular lens (IOL) options.
Hottest stories of 2014: Dry eye
Our editorial advisory board looks back on the top five dry eye stories of the year and discusses why these stories were important to optometry in 2014.
NaturalVue Multifocal 1 Day contact lens receives 501(k) clearance
Visioneering Technologies, Inc. (VTI) recently announced its NaturalVue Multifocal 1 Day Disposable (etafilcon A) contact lenses received U.S. Food and Drug Administration 510(k) clearance.
Health Canada approves Eyelea for DME treatment
Health Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
Support local eyecare providers this Small Business Saturday
While millions of people hit up the big box stores to grab the best deals on Black Friday, this Saturday is for the locals as communities across the country celebrate Small Business Saturday.
AAOphth’s IRIS database now used by one third of ECPs
The American Academy of Ophthalmology says that close to one-third of the nation's eye physicians and surgeons are participating in the Intelligent Research In Sight (IRIS) Registry, which is the first comprehensive database of eye diseases and conditions in the United States.
Actavis, Allergan CEOs talk acquisition
“The future is as bright as it’s ever been as a combined company—we’ll have an incredible amount of resources,” says Actavis CEO Brett Saunders. Saunders, Allergan CEO David Pyott, spoke exclusively with Optometry Times about the Allergan acquisition.